Skip to content
Peptigraph home

Cagrilintide and Semaglutide Together: What Is Known

Cagrilintide and Semaglutide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Amylin analogInvestigational (CagriSema component)CagrilintideInvestigational amylin analogue, not FDA-approved; a meta-analysis found cagrilintide monotherapy reduced body weight by a mean difference of -6.08%.[16]GLP-1 & metabolicGLP-1 agonistFDA approved (Ozempic, Wegovy, Rybelsus)SemaglutideFDA-approved GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus); in a 68-week trial in adults with obesity, mean weight change was -14.9% versus -2.4% with placebo.[17]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

  • REDEFINE 1: randomized trial of cagrilintide and semaglutide co-administered, versus each alone and placebo. · PMID 40544433
  • REDEFINE 2: co-administration of cagrilintide and semaglutide (CagriSema) in adults with type 2 diabetes. · PMID 40544432
  • Phase 1b randomized trial of multiple doses of cagrilintide given together with semaglutide 2.4 mg. · PMID 33894838
Cagrilintide is not FDA approved. The studies above describe research settings, not a recommendation to combine them. Ask the prescriber who manages both.
Each component

Side by side

Showing 9 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.

FieldCagrilintideSemaglutide
ClassAmylin analogGLP-1 agonist
Also calledcagri, cagsema, Ozempic, Wegovy, Rybelsus, Wegovy pill
FDA statusInvestigational (CagriSema component)FDA approved (Ozempic, Wegovy, Rybelsus)
WADAProhibited by WADA (S0)Cagrilintide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change.Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it.
Half-life159-195 h (with semaglutide 2.4 mg co-administered)subcutaneous · Lancet 2021, PMID 33894838approximately 1 weeksubcutaneous · FDA label (Ozempic)
Human studies we summarised4 human (4 randomized or controlled) of 7 summarised23 human (19 randomized or controlled) of 27 summarised
Typical study doses
Vial sizes sold2.5 mg, 5 mg, 10 mg2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
US searches per month33,100 · +96% searches368,000 · −38% searches

What people search

  • cagrilintide semaglutide390/mo
  • cagrilintide and semaglutide110/mo
  • semaglutide cagrilintide blend70/mo
  • semaglutide cagrilintide70/mo
  • semaglutide and cagrilintide70/mo
  • cagrilintide semaglutide dosage70/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
  3. 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  4. 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  5. 5Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
  6. 6Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
  7. 7Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
  8. 8Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
  9. 9These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
  11. 11Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  12. 12Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  13. 13PubMed search: (cagrilintide[tiab]) AND (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40544433Accessed 2 Oct 2026
  15. 15Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544432Accessed 2 Oct 2026
  16. 16Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.Annals of medicine and surgery (2012) · 2026PMID 42583410Accessed 2 Oct 2026
  17. 17Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026

Found an error? Report a correction.